Edition:
United States

Zealand Pharma A/S (ZELA.CO)

ZELA.CO on Copenhagen Stock Exchange

95.90DKK
6:38am EST
Change (% chg)

kr.2.80 (+3.01%)
Prev Close
kr.93.10
Open
kr.93.40
Day's High
kr.97.00
Day's Low
kr.93.40
Volume
59,600
Avg. Vol
130,969
52-wk High
kr.141.00
52-wk Low
kr.78.50

Latest Key Developments (Source: Significant Developments)

Zealand Pharma And Uniquest Collaborate To Develop Novel Drug Candidates
Tuesday, 20 Feb 2018 03:09am EST 

Feb 20 (Reuters) - Zealand Pharma A/S ::REG-ZEALAND PHARMA AND UNIQUEST COLLABORATE TO DEVELOP NOVEL DRUG CANDIDATES FOR GASTROINTESTINAL DISEASES.  Full Article

Zealand Reports Royalty Revenue Of DKK 11.3 Mln For Q4 2017
Wednesday, 7 Feb 2018 01:33am EST 

Feb 7 (Reuters) - ZEALAND PHARMA A/S ::REG-ZEALAND REPORTS ROYALTY REVENUE FOR THE FOURTH QUARTER OF 2017.ZEALAND REPORTS ROYALTY REVENUE OF DKK 11.3 MILLION/USD 1.8 MILLION FOR Q4 2017.‍IN Q4 SOLIQUA 100/33 SALES GREW 30% OVER PREVIOUS QUARTER​.ROYALTY REVENUE FOR 2017 AMOUNTED TO DKK 38.8 MILLION/USD 6.3 MILLION AN INCREASE OF 59% OVER PREVIOUS YEAR​.  Full Article

Zealand Pharma Makes Initial USD 1.5 Mln Equity Investment In Beta Bionics
Thursday, 21 Dec 2017 09:46am EST 

Dec 21 (Reuters) - ZEALAND PHARMA A/S ::ZEALAND PHARMA MAKES AN INITIAL USD 1.5 MILLION EQUITY INVESTMENT IN SERIES B OFFERING OF BETA BIONICS, INC..POTENTIAL FUTURE INVESTMENTS OF UP TO USD 3.5 MILLION ARE LINKED TO CLINICAL DEVELOPMENT MILESTONES.COLLABORATES WITH BETA BIONICS TO ADVANCE DEVELOPMENT OF ITS DASIGLUCAGON IN ILET(TM).  Full Article

Zealand Pharma Initiates Phase 3 Trial With Dasiglucagon
Thursday, 7 Dec 2017 09:36am EST 

Dec 7 (Reuters) - Zealand Pharma A/S ::ZEALAND PHARMA INITIATES THE PIVOTAL PHASE 3 TRIAL WITH DASIGLUCAGON FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA IN DIABETES.SAYS RESULTS FROM PHASE 3 TRIAL EXPECTED IN H2 2018​.  Full Article

Zealand Pharma Q3 operating loss at DKK 38.2 mln ​
Wednesday, 8 Nov 2017 09:00am EST 

Nov 8 (Reuters) - ZEALAND PHARMA A/S ::‍MAINTAINS ITS REVENUE GUIDANCE OF A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI.​.‍REVISED FINANCIAL GUIDANCE FOR 2017​.‍NET OPERATING EXPENSES IN 2017 ARE EXPECTED TO BE WITHIN RANGE OF DKK 375-385 MILLION, 4-6 % LOWER THAN PREVIOUSLY GUIDED​.‍NET OPERATING EXPENSES IN 2017 ARE EXPECTED TO BE WITHIN RANGE OF DKK 375-385 MILLION, 4-6 % LOWER THAN PREVIOUSLY GUIDED (DKK 390-410 MILLION).​.Q3 REVENUE DKK 40.1‍​ MILLION VERSUS DKK 39.6 MILLION YEAR AGO.2017 ‍OPERATING LOSS BEFORE ROYALTY INCOME/EXPENSES HAS BEEN REDUCED FROM DKK 290-310 MILLION TO DKK 275-285 MILLION​.‍FOR 2017, ZEALAND MAINTAINS ITS REVENUE GUIDANCE OF A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI​.Q3 OPERATING LOSS DKK 38.2 ‍​ MILLION VERSUS LOSS DKK 21.2 MILLION YEAR AGO.  Full Article

Zealand reports royalty revenue Of DKK 10.3 mln for Q3
Thursday, 2 Nov 2017 02:39am EDT 

Nov 2 (Reuters) - ZEALAND PHARMA A/S :REG- ZEALAND REPORTS ROYALTY REVENUE FOR THE THIRD QUARTER OF 2017.‍ZEALAND REPORTS ROYALTY REVENUE OF DKK 10.3 MILLION/USD 1.6 MILLION FOR Q3 2017​.  Full Article

Zealand Pharma granted orphan drug designation by FDA
Tuesday, 24 Oct 2017 06:43am EDT 

Oct 24 (Reuters) - ZEALAND PHARMA A/S ::REG-U.S. FDA GRANTS ORPHAN DRUG DESIGNATION TO GLEPAGLUTIDE FOR THE TREATMENT OF SHORT BOWEL SYNDROME.‍FDA OFFICE OF ORPHAN PRODUCTS DEVELOPMENT HAS GRANTED AN ORPHAN DRUG DESIGNATION TO GLEPAGLUTIDE​.  Full Article

Zealand Pharma to cooperate with Torrey Pines Institute for Molecular Studies
Wednesday, 4 Oct 2017 05:29am EDT 

Oct 4 (Reuters) - ZEALAND PHARMA A/S :REG-ZEALAND PHARMA AND TORREY PINES INSTITUTE FOR MOLECULAR STUDIES ANNOUNCE RESEARCH COLLABORATION.‍PARTIES TO COOPERATE IN ORDER TO IDENTIFY NOVEL PEPTIDE THERAPEUTICS USING TPIMS'S PROPRIETARY PEPTIDE LIBRARIES​.  Full Article

Edge Therapeutics appoints Rosemary Crane to Board of Directors
Tuesday, 19 Sep 2017 07:00am EDT 

Sept 19 (Reuters) - Edge Therapeutics Inc :Edge Therapeutics appoints Rosemary A Crane, pharmaceutical industry leader, to its Board Of Directors.Edge Therapeutics Inc - ‍Crane's appointment expands Board of Directors to 10 members, eight of whom are independent​.Edge Therapeutics Inc - ‍Crane currently serves as a Director of Teva Pharmaceuticals and as vice chairman of Board of Zealand Pharma A/S​.  Full Article

Zealand Pharma and Orbit Discovery enter into research collaboration
Thursday, 7 Sep 2017 04:07am EDT 

Sept 7 (Reuters) - ZEALAND PHARMA A/S ::REG-ZEALAND AND ORBIT DISCOVERY ENTER INTO RESEARCH COLLABORATION.ZEALAND PHARMA A/S - ‍ZEALAND AND ORBIT ANNOUNCE THAT THEY ENTERED INTO MULTI-TARGET RESEARCH COLLABORATION TO IDENTIFY PEPTIDE THERAPEUTICS USING ORBIT'S PEPTIDE DISPLAY TECHNOLOGY​.  Full Article

BRIEF-Zealand Pharma And Uniquest Collaborate To Develop Novel Drug Candidates

* REG-ZEALAND PHARMA AND UNIQUEST COLLABORATE TO DEVELOP NOVEL DRUG CANDIDATES FOR GASTROINTESTINAL DISEASES Source text for Eikon: Further company coverage: (Gdynia Newsroom)